web analytics

Imfinzi is first immunotherapy to show both significant survival benefitand improved, durable responses in extensive-stage small cell lung cancer

9 Sept 2019 08:38 BST

Imfinzi is first immunotherapy to show both significant survival benefit
and improved, durable responses in extensive-stage small cell lung cancer 

In the Phase III CASPIAN trial Imfinzi at a fixed, convenient dose improved
survival with either a cisplatin or carboplatin chemotherapy backbone

AstraZeneca today presented detailed results from the Phase III CASPIAN trial, showing Imfinzi (durvalumab) significantly improved overall survival (OS) in patients with previously-untreated extensive-stage small cell lung cancer (SCLC).

Imfinzi in combination with

Source: Imfinzi is first immunotherapy to show both significant survival benefitand improved, durable responses in extensive-stage small cell lung cancer

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.